Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
Authors
Keywords
-
Journal
PLoS One
Volume 17, Issue 8, Pages e0273340
Publisher
Public Library of Science (PLoS)
Online
2022-08-25
DOI
10.1371/journal.pone.0273340
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study
- (2022) Gustavo Gomes Resende et al. Infectious Diseases
- Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial
- (2021) Iñigo Les Bujanda et al. Trials
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia
- (2021) André Santa Cruz et al. Frontiers in Immunology
- Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database
- (2021) Jaykaran Charan et al. Expert Opinion On Drug Safety
- The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
- (2021) Andreas Neubauer et al. LEUKEMIA
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- The Role of Th17 Response in COVID-19
- (2021) Diana Martonik et al. Cells
- Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
- (2021) Luís Puig et al. Dermatology and Therapy
- Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study
- (2021) Sergey N. Avdeev et al. CYTOKINE
- Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials
- (2021) Samiksha Gupta et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
- (2020) Tobias Herold et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
- (2020) Dandan Wu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of the Inflammatory Response to Severe COVID-19 Illness
- (2020) Oliver J McElvaney et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19
- (2020) Milo Gatti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID‐19
- (2020) Natasha N. Pettit et al. JOURNAL OF MEDICAL VIROLOGY
- COVID-19 revisiting inflammatory pathways of arthritis
- (2020) Georg Schett et al. Nature Reviews Rheumatology
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
- (2020) Sarah C.J. Jorgensen et al. PHARMACOTHERAPY
- National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 – a prospective cohort study
- (2020) Marius Myrstad et al. Scandinavian Journal of Trauma Resuscitation & Emergency Medicine
- Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
- (2020) Sara De Biasi et al. Nature Communications
- Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
- (2020) Fabrizio Cantini et al. DRUGS
- Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19
- (2020) Xiuhong Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
- (2020) Daniel E Leisman et al. Lancet Respiratory Medicine
- Cytokine profile and disease severity in patients with COVID-19
- (2020) Ali Ghazavi et al. CYTOKINE
- Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease
- (2020) Hamidreza Samaee et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The performance of the National Early Warning Score and National Early Warning Score 2 in hospitalised patients infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- (2020) Ina Kostakis et al. RESUSCITATION
- The National Early Warning Score 2 (NEWS2)
- (2019) Gary B Smith et al. CLINICAL MEDICINE
- MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile
- (2018) Waleed H. Mahallawi et al. CYTOKINE
- Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
- (2018) Satoshi Kubo et al. Frontiers in Immunology
- Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology
- (2017) Peter A. Szabo et al. JOURNAL OF IMMUNOLOGY
- Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
- (2017) Edward C. Keystone et al. JOURNAL OF RHEUMATOLOGY
- Role of IL-17 in LPS-induced acute lung injury: an in vivo study
- (2017) Qi Ding et al. Oncotarget
- Tocilizumab (Actemra)
- (2017) Martin Sheppard et al. Human Vaccines & Immunotherapeutics
- Interleukin-17A Is Associated With Alveolar Inflammation and Poor Outcomes in Acute Respiratory Distress Syndrome
- (2016) Carmen Mikacenic et al. CRITICAL CARE MEDICINE
- Unexpected Role for Adaptive αβTh17 Cells in Acute Respiratory Distress Syndrome
- (2015) John T. Li et al. JOURNAL OF IMMUNOLOGY
- Bone marrow transplantation alters lung antigen-presenting cells to promote TH17 response and the development of pneumonitis and fibrosis following gammaherpesvirus infection
- (2015) X Zhou et al. Mucosal Immunology
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection
- (2013) Rodrigo Guabiraba et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interleukin-17 Promotes Autoimmunity by Triggering a Positive-Feedback Loop via Interleukin-6 Induction
- (2008) Hideki Ogura et al. IMMUNITY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started